New directions for frontotemporal dementia drug discovery.
This report summarizes the recommendations of the Frontotemporal Dementia (FTD) Working Group on FTD Drug Discovery that was part of an international FTD Workshop held on January 18 and 19, 2007, in Miami, Florida. The workshop was sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA) of the National Institutes of Health (NIH) and the Association for Frontotemporal Dementia (AFTD) with the express purpose of defining opportunities to improve the diagnosis and treatment of patients affected by a neurodegenerative disorder classified as one of the many variants of FTD. The recognition that almost all forms of FTD are due to TDP-43 proteinopathies and tauopathies creates new opportunities for FTD drug discovery targeting pathways of TDP-43 and tau-mediated neurodegeneration.
Trojanowski
John Q
JQ
Institute on Aging, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. trojanow@mail.med.upenn.edu
Duff
Karen
K
Fillit
Howard
H
Koroshetz
Walter
W
Kuret
Jeff
J
Murphy
Diane
D
Refolo
Larry
L
D000818:Animals; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans